CLINICAL STUDY

Raloxifene decreases serum IGF-I in male patients with active acromegaly

Eleni V Dimaraki, Kathleen V Symons and Ariel L Barkan

Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Michigan and the Department of Veterans Affairs Medical Center, Ann Arbor, Michigan 48109, USA

(Correspondence should be addressed to A L Barkan, 3920 Taubman Center, Box 0354, Ann Arbor, Michigan 48109, USA; Email: abarkan@umich.edu)

Abstract

Objective: Most patients with acromegaly require additional treatments after trans-sphenoidal surgery. Although traditional methods of treatment aim at suppressing GH hypersecretion from the pituitary tumor, recent studies on the use of the GH receptor antagonist have shown that targeting the action of GH on peripheral tissues may be more effective. Estrogens and the selective estrogen receptor modulator tamoxifen have been used previously to suppress circulating IGF-I levels in patients with acromegaly. Positive effects of raloxifene in women with active acromegaly have been reported recently. This study was designed to examine the potential role of raloxifene in the treatment of acromegaly in male patients.

Design: We studied eight men with active acromegaly despite the fact that they were receiving traditional treatments. All subjects were treated with raloxifene (60 mg twice a day) for a median of 5 weeks.

Methods: The effects of raloxifene on GH secretion were assessed by obtaining 24-h GH profiles and studying the response of GH to various stimuli before and after treatment with raloxifene. Serum IGF-I was measured before and after raloxifene treatment.

Results: Raloxifene did not affect basal GH secretion or response of GH to TRH, GHRH or glucose, but it decreased circulating IGF-I by 16 ± 4% (P = 0.001), and normalized plasma IGF-I in two patients. No changes in clinical parameters were observed. Prolactin levels, the prolactin response to TRH and free testosterone levels remained unchanged. Raloxifene was well tolerated.

Conclusion: Raloxifene might be useful in the treatment of male patients with active acromegaly, but longer term studies are clearly needed.

European Journal of Endocrinology 150 481–487

Introduction

Traditionally, treatment of acromegaly is directed at the pituitary tumor with the goal of normalization of growth hormone (GH) hypersecretion. Trans-sphenoidal surgery (TSS), radiotherapy, dopamine agonists and somatostatin analogs all have less than 100% efficacy (1–4), and significant adverse effects.

Plasma insulin-like growth factor-I (IGF-I) is now considered a sensitive and specific diagnostic marker of acromegaly and has become the gold-standard test in following its activity (5–8). Normalization of plasma IGF-I by the GH antagonist pegvisomant resulted in clinical improvement (9, 10), demonstrating that targeting the GH action and IGF-I production instead of the GH secretion by the tumor is both safe and effective. However, pegvisomant needs to be administered parenterally and is very expensive.

Long before a GH antagonist became available, estrogens and the selective estrogen receptor modulator (SERM) tamoxifen were used to block the action of GH and suppress plasma IGF-I levels (11–16). Both suppress IGF-I production in vitro and in vivo in humans (17–22). In patients with acromegaly, estrogens and tamoxifen suppressed IGF-I by 55% and 45% respectively (14, 16, 23) and, in some studies, the IGF-I suppression was accompanied by clinical improvement.

The newer SERM raloxifene has a more favorable safety profile than estrogen or tamoxifen and has been shown to decrease IGF-I in healthy women and in women with acromegaly (24–26). However, its safety and efficacy profiles have not been tested in men with acromegaly. This study was designed to examine the safety and efficacy of raloxifene in male patients with acromegaly.
Subjects and methods

Subjects

The study was performed at the General Clinical Research Center (GCRC) of the University of Michigan. It was approved by the Institutional Review Board of the University of Michigan. We studied eight Caucasian men with active acromegaly (age 34–63 years, median 41.5 years). All patients signed the informed consent document prior to their participation in the study. All subjects had had TSS that failed to normalize serum IGF-I levels 1–18 years (median 4 years) prior to their enrollment. Two patients had been on octreotide LAR (Long Acting Release) for more than 6 months prior to their enrollment without normalization of their IGF-I levels and they continued on the same dose of octreotide LAR for the duration of the study. Three patients had at least one anterior pituitary hormone deficiency and one patient had diabetes insipidus. Patients with pituitary hormone deficiencies were on appropriate hormone replacement that was not changed during their participation in the study. Two patients were on testosterone replacement therapy.

Study design

All subjects received raloxifene (60 mg twice a day) for 3.3–6.0 weeks (median 5 weeks). Raloxifene (Evista) was a gift from Lilly (Indianapolis, IN, USA). Seven out of eight subjects were admitted to the GCRC twice, prior to and at the end of raloxifene treatment. Another subject had only serum IGF-I measured before and during treatment with raloxifene. Each subject was admitted to the GCRC at 1700 h on day 1. Before any invasive procedures, they completed a quality of life questionnaire and an acromegaly-specific symptom questionnaire. At the time of the second admission to assess compliance with the raloxifene regimen.

Assays

Plasma GH was measured by a chemiluminometric assay with a sensitivity of 0.01 ng/ml, and intra-assay coefficient of variation (CV) less than 10% (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). Plasma IGF-I was measured by a two-site immunoradiometric assay (Diagnostic Systems Laboratories, Webster, TX, USA). Age- and gender-adjusted normal ranges were used. The intra-assay CV is 4%. Prolactin was measured by a chemiluminometric assay (Ortho-Clinical Diagnostics, Amersham, Bucks, UK) with a normal range of 3–23 ng/ml and intra-assay CV 6%. Insulin was measured by a chemiluminometric assay (Diagnostic Products Corporation, Los Angeles, CA, USA) with a sensitivity of 2 μU/ml and intra-assay CV of 4%. Free testosterone was measured by a radioimmunoassay (Diagnostic Products Corporation) with a normal range of 10–30 pg/ml and intra-assay CV of less than 10%. Lipid levels were measured by the Clinical Pathology Laboratory of the University of Michigan using commercial methods.

For all assays, all samples from each subject were run in the same assay to minimize variability of the measurements. Glucose was measured by Beckman analyzer.

Data analysis

The 24-h mean GH was calculated as the average of the plasma GH values over 24 h. The GH response to TRH, GHRH and OGTT and the prolactin response to TRH were calculated as the area under the curve (AUC) of GH vs time using the trapezoidal rule. The serum IGF-I values were expressed both as absolute values and as the ratio to the gender- and age-specific upper normal limit (UNL). Changes in clinical parameters, mean GH values and serum IGF-I levels as well as the GH responses to TRH, GHRH and OGTT before and after treatment with raloxifene were compared by paired t-tests after logarithmic transformation of the data where appropriate. The results are presented as means ± S.E.M.

Results

Clinical parameters

Administration of raloxifene did not result in changes in hand volume or finger size. There was also no
improvement of any symptoms, including headache, perspiration, arthralgias, fatigue and soft-tissue swelling as assessed by the self-administered questionnaire (data not shown). Raloxifene was well tolerated by all subjects. Specifically, no changes in sexual function were reported.

**Serum IGF-I and 24-h mean GH**

During treatment with raloxifene, serum IGF-I decreased in all subjects by an average of 16±4% (520±80 vs 604±72 µg/l, P = 0.0011). When serum IGF-I values were expressed as the ratio to the UNL, the results were similar (1.68±0.27 vs 1.94±0.25, P = 0.0006). Serum IGF-I normalized in two of the eight subjects (Fig. 1).

Mean GH remained unchanged during raloxifene treatment (2.4±0.5 vs 2.7±0.9 µg/l, P = 0.56) (Fig. 2).

**TRH and GHRH stimulation tests (Fig. 3)**

The plasma GH responses to i.v. TRH or GHRH were not affected by raloxifene treatment (P = 0.81 and P = 0.48 respectively). The baseline serum prolactin concentrations (12.9±3.8 vs 13.1±3.5 ng/ml, P = 0.52), and the prolactin responses to TRH (P = 0.59) were unchanged.

**OGTT (Fig. 4)**

Fasting blood glucose levels were similar during baseline and raloxifene treatment (96±5 vs 101±5 mg/dl, P = 0.41). The same was true for fasting plasma insulin concentrations (9.7±2.7 vs 10.1±2.0 µU/ml, P = 0.69), and fasting insulin to glucose ratio (P = 0.77). However, there was an increase in the blood glucose AUC during raloxifene treatment (20±6%, P = 0.015). In the entire group, there was no overall change in the insulin responses to the glucose load (P = 0.51), but the plasma insulin AUC increased by 47±23% in five out of six subjects and decreased by 36% in one subject. The GH response to OGTT was not influenced by the treatment with raloxifene (P = 0.89).

In the subjects who were not on testosterone replacement therapy (n = 5), free testosterone was not affected by treatment with raloxifene (14.6±1.8 vs 19.1±3.5 pg/ml, P = 0.17). Only one of five patients had free testosterone levels below the normal range both before and after treatment with raloxifene. Plasma lipid levels also remained unchanged (data not shown).

**Discussion**

Despite the recent progress in the management of acromegaly, there is still a large number of patients who
have active disease, defined as the presence of symptoms and elevated plasma IGF-I levels following TSS, radiotherapy or treatment with somatostatin analogs and/or dopamine agonists. The GH antagonist pegvisomant is the most promising and efficacious treatment for acromegaly (9, 10). However, the high cost of available medications and the need for parenteral administration of somatostatin analogs and pegvisomant can limit access to treatment.

Pegvisomant blocks GH action on the liver and other peripheral tissues, resulting in normalization of IGF-I in more than 95% of patients with acromegaly and in clinical improvement (9, 10). However, the high cost of available medications and the need for parenteral administration of somatostatin analogs and pegvisomant can limit access to treatment.

Pegvisomant blocks GH action on the liver and other peripheral tissues, resulting in normalization of IGF-I in more than 95% of patients with acromegaly and in clinical improvement (9, 10). However, the high cost of available medications and the need for parenteral administration of somatostatin analogs and pegvisomant can limit access to treatment.

In healthy women, oral estrogen suppressed serum IGF-I levels (27) and, in women with GH deficiency, oral estrogen increased GH requirements to achieve the same level of plasma IGF-I (28). This effect is not mediated through suppression of GH secretion, since estrogen actually results in increased GH secretion in humans (29). Estrogen could decrease IGF-I production either by directly suppressing IGF-I expression or through suppressing GH receptor (GHR) expression. In rabbits, estrogen inhibits hepatic IGF-I production by inhibiting the expression of the GHR gene (30).

SERMs also suppress IGF-I secretion. Tamoxifen suppressed plasma IGF-I by 40–50% in women with breast cancer (19, 31), and by 24% in healthy women (18). Unlike estrogen, tamoxifen may also suppress GH secretion. Tamoxifen reduced GH secretion from cultured human somatotroph adenoma cells (32), and from lamb pituitary cells in vitro (33). In vivo, it decreased GH secretion in pubertal boys and adult males (34, 35), and suppressed the GH response to GHRH stimulation in women in one study (22). Another SERM, droluxifene, also suppressed IGF-I levels in a dose-dependent fashion in women with breast cancer (36).

In acromegaly, men have higher IGF-I levels than women with the same fasting GH levels and women on oral estrogen replacement have even lower IGF-I levels (37). Both oral estrogen and tamoxifen have been tried in patients with acromegaly in an effort to decrease circulating IGF-I levels and improve clinical manifestations. Estrogen administration resulted in improvement in glucose tolerance within days of treatment (13), changes in body composition (23) and, in one study, estrogen decreased hand volume (15). Estrogen did not suppress GH secretion (13), but rather decreased the bioactivity of serum sulfation factor (bioassayable IGF-I) (12). Using a sensitive radioimmunoassay for IGF-I, Clemmons et al. (14) showed that oral ethinyl estradiol decreased immuno-reactive IGF-I by 47% within 48 h after initiation of treatment in patients with acromegaly, accompanied by decreased phosphate and hydroxyproline clearance and decreased fasting blood glucose.

In one study, tamoxifen decreased circulating IGF-I levels by 18–60% in 13 out of 19 patients with acromegaly, and normalized IGF-I in three patients (17). There was a small increase in GH levels (16). Therefore, like estrogen, tamoxifen primarily inhibited hepatic production of IGF-I.

The effects of raloxifene on the liver and the production of IGF-I are qualitatively similar to those of estrogen and tamoxifen. Raloxifene decreased plasma IGF-I and the response of IGF-I to exogenous GH stimulation in postmenopausal women (25, 26, 38). In one recent study, 13 women with acromegaly

![Figure 4](https://www.eje.org)
received raloxifene (60 mg daily) for 1–12 months (24). IGF-I was suppressed by more than 30% in ten out of 13 patients, and in some patients this was accompanied by a decrease in ring size.

Whereas estrogen cannot be used in men with acromegaly because of predictable adverse effects such as gynecomastia, decreased libido and erectile dysfunction, the theoretical absence of these adverse effects with raloxifene makes this medication a potential means of decreasing IGF-I levels in male patients with active acromegaly. We have shown that raloxifene induced a small but significant decrease in plasma IGF-I and was able to normalize IGF-I in two out of eight male patients with treatment-resistant acromegaly, without influencing GH secretion and without causing gynecomastia, changes in libido or erectile dysfunction. We did not observe any clinical improvement of the acromegalid syndrome in these patients. The effects of raloxifene on our patients were less pronounced than in female patients. It is possible that our patients responded less because they were men, or because they were treated for a shorter period. The lack of improvement in clinical parameters in our subjects might also be due to the shorter period of treatment.

The degree of IGF-I suppression observed in this study is also lower than the suppression of IGF-I by estrogen or other SERMs (14, 16, 36), but similar to the suppression of IGF-I by raloxifene in postmenopausal women (26). In a recent study (39) it was shown that raloxifene was less effective than estradiol in suppressing IGF-I in GH-deficient and postmenopausal women. Treatment of postmenopausal women with a large dose of raloxifene (600 mg/day) did not have any additional effect on IGF-I (26). Therefore, treatment with higher doses would be unlikely to benefit our patients with acromegaly.

The clinical significance of decreasing circulating IGF-I without suppressing GH secretion is unclear. Oral estrogen and the GH antagonist result in clinical improvement of acromegaly despite the increase in circulating GH levels (9, 15). Serum IGF-I is a reliable marker of the response to surgery, radiation therapy or octreotide treatment in acromegaly, as it reflects the suppression of GH output from the pituitary tumor. In the case of the GH antagonist, serum IGF-I is the only marker of response to treatment, but it is an index of the blockade of GHRs not only in the liver but also at other tissues, such as muscle and bone. Therefore, raloxifene would be effective if circulating IGF-I of hepatic origin is responsible for the majority of acromegaly manifestations or if raloxifene is able to antagonize GH and suppress IGF-I production in other peripheral tissues in addition to the liver.

Although raloxifene exerted an estrogen-like effect on the pituitary by increasing prolactin and suppressing gonadotropins in rats (40, 41), in our patients the prolactin response to TRH stimulation and the serum testosterone levels remained unaffected, suggesting the absence of a significant effect of raloxifene on the human pituitary gland.

Our observations on the effects of raloxifene on glucose and insulin levels are of interest, since they suggest a decrease in insulin sensitivity. This is in contrast to the results of other studies (24, 25, 38, 42, 43). It is possible that the decrease in insulin sensitivity in our study was due to the higher doses of raloxifene, the shorter period of treatment or the gender of patients.

We have concluded that raloxifene had a mild but significant suppressive effect on IGF-I that is of unclear clinical significance in patients with acromegaly. A therapeutic trial of raloxifene may be justifiable if other, more effective, measures to control active acromegaly are either not tolerated or not available, especially in patients with mildly elevated plasma IGF-I concentrations and mild clinical symptoms. Raloxifene should be given with caution in patients with diabetes mellitus or impaired glucose tolerance since there is a possibility it could worsen insulin sensitivity. The design of new SERMs with estrogen-like activity at the hepatic level and anti-estrogenic effect at the pituitary level might result in a more effective second line treatment for acromegaly. Further studies of the effect of estrogen and SERMs on the expression of IGF-I in the non-hepatic tissues would be valuable.

Acknowledgements

This work was supported by the Lilly Pituitary Scholars Fellowship (to E V D), the VA Medical Research Service Merit Award (to A L B) and GCRC grant no. M01-RR00042.

References


www.eje.org


Received 4 September 2003
Accepted 11 December 2003